Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Oncofertility w praktyce klin.
  • Obniżka

Zobacz nowsze wydanie:

Parkinson's Disease and Related Disorders Part II
Parkinson's Disease and Related Disorders Part II

Parkinson's Disease and Related Disorders Part II

Handbook of Clinical Neurology Series

9781416048190
982,80 zł
884,52 zł Zniżka 98,28 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 884,52 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
A volume in the Handbook of Clinical Neurology series on Parkinsons Disease and related disorders. Note that this is Part II of a two volume set on Parkinsons Disease by Koller and Melamed.
Szczegóły produktu
Churchill Livingstone
35012
9781416048190
9781416048190

Opis

Rok wydania
2007
Numer wydania
1
Oprawa
twarda
Liczba stron
530
  • Section 5 Medical Treatment of Parkinsons Disease

    30. Physical therapy in Parkinsons disease
    Jean-Michel Gracies, Winona Tse, Mara Lugassy and Judith Frank (New York, NY, USA)
    31. Neuroprotection in Parkinsons disease: clinical trials
    Fabrizio Stocchi (Rome, Italy)
    32. Levodopa
    Thomas D. Hälbig and William C. Koller (New York, NY and Chapel Hill, NC, USA)
    33. Dopamine agonists
    Olivier Rascol, Tarik Slaoui, Wafa Regragui, Fabiene Ory-magne, Christine Brefel-Courbon and Jean-Louis Montastruc (Toulouse, France)
    34. Monoamine oxidase A and B inhibitors in Parkinsons disease
    Moussa B. H. Youdim and Peter F. Riederer (Haifa, Israel and Würzburg, Germany)
    35. Anticholinergic medications
    Yaroslau Compta and Eduardo Tolosa (Barcelona, Spain)
    36. Antiglutamatergic drugs in the treatment of Parkinsons disease
    Maria Graciela Cersósimo and Federico Eduardo Micheli (Buenos Aires, Argentina)
    37. Investigational drugs
    Carlo Colosimo and Giovanni Fabbrini (Rome, Italy)
    38. The importance of patients groups and collaboration
    Mary Baker and Jill Rasmussen (Sevenoaks and Redhill, UK)

    Section 6 Complications of therapy

    39. Motor and non-motor fluctuations
    Susan H. Fox and Anthony E. Lang (Toronto, Canada)
    40. Levodopa-induced dyskinesias in Parkinsons disease
    Jose A. Obeso, Marcelo Merello, Maria C. Rodríguez-Oroz, Concepció Marin, Jorge Guridi, Lazaro Alvarez (Buenos Aires, Argentina, Pamplona and Barcelona, Spain and La Habana, Cuba)
    41. Treatment induced mental changes in Parkinsons disease
    Kelvin L. Chou and Joseph H. Friedman (Warwick, RI, USA)

    Section 7 Surgical treatment

    42. Ablative surgery for the treatment of Parkinsons disease
    Frederick A. Lenz (Baltimore, MD, USA)
    43. Deep brain stimulation
    J. Volkmann and G. Deuschl (Kiel, Germany)
    44. Transplantation
    Curt R. Freed (TBC) (Denver, CO, USA)
    45. Gene therapy approaches for the treatment of Parkinsons disease
    Biplob Dass and Jeffrey H. Kordower (Chicago, IL, USA)

    Section 7 Other parkinsonian disease syndromes

    46. Multiple system atrophy
    Ronald F. Pfeiffer (Memphis, TN, USA)
    47. Progressive supranuclear palsy
    David J. Burn and Andrew J. Lees (Newcastle upon Tyne and London, UK)
    48. Corticobasal degeneration
    Natividad P. Stover, Harrison C. Walker and Ray L. Watts (Birmingham, AL, USA)
    49. Infectious basis to the pathogenesis of Parkinsons disease
    V. Dhawan and K. Ray Chaudhuri (London, UK)
    50. Toxic causes of Parkinsons disease
    Nirit Lev, Eldad Melamed and Daniel Offen (Petah-Tikva and Tel-Aviv, Israel)
    51. Drug induced parkinsonism
    Federico Micheli and María Graciela Cersosimo (Buenos Aires, Argentina)
    52. Vascular parkinsonism
    Yacov Balash and Amos D. Korczyn (Tel-Aviv and Ramat-Aviv, Israel)
    53. Old age and Parkinsons disease
    Alex Rajput and Ali H. Rajput (Saskatoon, Canada)
    54. Other degenerative processes
    J. Carsten Möller and Wolfgang H. Oertel (Marburg, Germany)
    55. Hydrocephalus and structural lesions
    John G.L. Morris, Brian Owler, Mariese A. Hely and Victor S.C. Fung (Sydney, Australia)
    56. Calcification of the basal ganglia
    Jennifer S. Hui and Mark F. Lew (Los Angeles, CA, USA)
    57. Trauma and Parkinsons disease
    Oscar S. Gershanik (Buenos Aires, Argentina)
    58. Psychogenic parkinsonism
    Vasiliki Koukouni and Kailash P. Bhatia (London, USA)
    59. Parkinsonism and dystonia
    Ruth H. Walker (new York, NY, USA)
    60. Dementia with Lewy bodies
    Ian McKeith (Newcastle upon Tyne, UK)
    61. Myoclonus and parkinsonism
    Daniel D. Truong and Roongroj Bhidayasiri (Los Angeles, CA, USA and Bangkok, Thailand)

Zobacz nowsze wydanie:

Parkinson's Disease and Related Disorders Part II
Parkinson's Disease and Related Disorders Part II
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów